BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Results Earnings Conference Call May 9, 2024 8:00 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer and Founder
Vincent O'Neill - Executive Vice President and Chief of Product Development and Medical Officer
Richard Steinhart - Senior Vice President and Chief Financial Officer
Matt Wiley - Senior Vice President and Chief Commercial Officer
Robert Risinger - Chief Medical Officer, Neuroscience
Conference Call Participants
Colin Bristow - UBS
Ram Selvaraju - H.C. Wainwright
Alec Stranahan - Bank of America
Avantika Joshi - Mizuho Securities
Sumant Kulkarni - Canaccord Genuity
Samir Devani - Rx Securities
Operator
Good morning. And welcome to the BioXcel Therapeutics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions].
Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in those forward-looking statements.
Risk factors that may affect future results are detailed in the company's annual report on Form 10-K for the year ended December 31, 2024 (sic) [2023], which can be found at www.bioxceltherapeutics.com or on www.sec.gov, and which will be updated in its quarterly report on Form 10-Q for the quarterly period ended March 31, 2024.
As a reminder, today's call is being recorded.
Speaking on today's call are Dr. Vimal Mehta, Chief Executive Officer; Dr. Vince O'Neill, Chief of Product Development and Medical Officer; and Richard Steinhart, Chief Financial Officer. They will be joined in the Q&A session by Dr. Frank Yocca, Chief Scientific Officer; Matt Wiley, Chief Commercial Officer; and Dr. Rob Risinger, Chief Medical Officer of Neuroscience.
It's now my pleasure to turn the call over to Dr. Mehta. Please go ahead.
Vimal Mehta
Good morning. And thank you for joining us. 2024 has been an important period of progress for BioXcel Therapeutics, both at the program and corporate level.
Starting with our neuroscience program, our journey with BXCL501 is well underway to expand the market potential for our agitation portfolio into the retail setting. We are focused on potentially bringing this novel treatment option for bipolar and schizophrenia-related agitation into the home setting.
We are also dedicated to expanding into a much larger indication, Alzheimer's-related agitation, both in the in-care and home setting. We believe these two opportunities are unique, with no known FDA-approved therapies, and represent transformative value drivers for the company and our shareholders.